Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the ...

New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocyt ...

Lyell management will host an investor webcast with presenting author and ronde-cel investigator Sarah M. Larson, MD, ...

An expert discusses IL-18-armored CAR T cells for adults with relapsed B-cell leukemia, showing complete remissions with ...

In a significant move within the biopharmaceutical sector, Sanofi has once again turned to Dren Bio, committing an impressive $100 million upfront for further development of B cell depletion therapies ...

Non-Hodgkin lymphoma (NHL) is a form of cancer that begins in the lymph system. B-cell NHLs affect immune cells known as B lymphocytes or B cells. All forms of NHL begin in lymphocytes. These white ...

Scientists have identified a promising strategy to improve liver cancer immunotherapy: targeting B-cells. While immunotherapy ...